Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis

JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis

(2018) Leandro Ladislau et al.   BRAIN

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

(2018) Gina A. Montealegre Sanchez et al.   JOURNAL OF CLINICAL INVESTIGATION

Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort

(2017) Sarah L. Tansley et al.   JOURNAL OF AUTOIMMUNITY

Treatment of Juvenile Dermatomyositis: An Update

(2017) Charalampia Papadopoulou et al.   PEDIATRIC DRUGS

Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis

(2017) Ebun Omoyinmi et al.   PLoS One

Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis

(2016) Raquel Campanilho-Marques et al.   ARTHRITIS CARE & RESEARCH

Type I interferon pathway in adult and juvenile dermatomyositis

(2011) Emily C Baechler et al.   ARTHRITIS RESEARCH & THERAPY

Endothelial injury and repair in systemic vasculitis of the young

(2010) L. A. Clarke et al.   ARTHRITIS AND RHEUMATISM

The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis

(2010) Nicolino Ruperto et al.   ARTHRITIS CARE & RESEARCH